3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
31
Squamous Cell Carcinoma of Head and Neck
21
Carcinoma, Non-Small-Cell Lung
20
Neoplasms
18
Breast Neoplasms
18
Glioblastoma
17
Esophageal Squamous Cell Carcinoma
16
Rectal Neoplasms
15
Lung Neoplasms
15
Esophageal Neoplasms
15
Head and Neck Neoplasms
12
Uterine Cervical Neoplasms
11
Neoplasm Metastasis
10
Glioma
10
Nasopharyngeal Carcinoma
8
Stomach Neoplasms
7
Radiation Injuries
7
Oropharyngeal Neoplasms
7
Brain Neoplasms
7
Hyperthermia
6
Carcinoma, Hepatocellular
6
Astrocytoma
6
Urinary Bladder Neoplasms
5
Small Cell Lung Carcinoma
5
Sarcoma
5
Oligodendroglioma
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Interventions
Cyclophosphamide
7
venetoclax
6
Azacitidine
6
fludarabine
5
Cytarabine
4
Blood Specimen Collection
4
daratumumab
3
Lenalidomide
3
Daunorubicin
3
tislelizumab
2
fludarabine phosphate
2
Rituximab
2
Liquid Biopsy
2
Idarubicin
2
Gemtuzumab
2
Capecitabine
2
Busulfan
2
trastuzumab deruxtecan
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sugemalimab
1
sacituzumab govitecan
1
relugolix
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
ivosidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm, Residual
×
Radiotherapy
×
Clear all
NCT05929222
2026-06-01
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3
Recruiting
190 enrolled